Vascular Endothelial Growth Factor C/Vascular Endothelial Growth Factor Receptor 3 Signaling Regulates Chemokine Gradients and Lymphocyte Migration From Tissues to Lymphatics

被引:28
|
作者
Iwami, Daiki [1 ]
Brinkman, C. Colin [1 ]
Bromberg, Jonathan S. [1 ,2 ,3 ]
机构
[1] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 20201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 20201 USA
[3] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 20201 USA
关键词
NORMAL HUMAN KERATINOCYTES; CHRONIC SKIN INFLAMMATION; MATRIX HEPARAN-SULFATE; DENDRITIC CELLS; VEGF-C; AFFERENT LYMPHATICS; PERIPHERAL-TISSUES; CARDIAC ALLOGRAFTS; BLOOD-PRESSURE; MOUSE TAIL;
D O I
10.1097/TP.0000000000000561
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Circulation of leukocytes via blood, tissue and lymph is integral to adaptive immunity. Afferent lymphatics form CCL21 gradients to guide dendritic cells and T cells to lymphatics and then to draining lymph nodes (dLN). Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 (VEGFR-3) are the major lymphatic growth factor and receptor. We hypothesized these molecules also regulate chemokine gradients and lymphatic migration. Methods. CD4(+) T cells were injected into the foot pad or ear pinnae, and migration to afferent lymphatics and dLN quantified by flow cytometry or whole mount immunohistochemistry. Vascular endothelial growth factor receptor 3 or its signaling or downstream actions were modified with blocking monoclonal antibodies (mAbs) or other reagents. Results. Anti-VEGFR-3 prevented migration of CD4+ Tcells into lymphatic lumen and significantly decreased the number that migrated to dLN. Anti-VEGFR-3 abolished CCL21 gradients around lymphatics, although CCL21 production was not inhibited. Heparan sulfate (HS), critical to establish CCL21 gradients, was down-regulated around lymphatics by anti-VEGFR-3 and this was dependent on heparanase-mediated degradation. Moreover, a Phosphoinositide 3-kinase (PI3K)alpha inhibitor disrupted HS and CCL21 gradients, whereas a PI3K activator prevented the effects of anti-VEGFR-3. During contact hypersensitivity, VEGFR-3, CCL21, and HS expression were all attenuated, and anti-heparanase or PI3K activator reversed these effects. Conclusions. Vascular endothelial growth factor C/VEGFR-3 signaling through PI3K alpha regulates the activity of heparanase, which modifies HS and CCL21 gradients around lymphatics. The functional and physical linkages of these molecules regulate lymphatic migration from tissues to dLN. These represent new therapeutic targets to influence immunity and inflammation.
引用
收藏
页码:668 / 677
页数:10
相关论文
共 50 条
  • [1] Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis
    Mimura, T
    Amano, S
    Usui, T
    Kaji, Y
    Oshika, T
    Ishii, Y
    [J]. EXPERIMENTAL EYE RESEARCH, 2001, 72 (01) : 71 - 78
  • [2] DEVELOPMENTAL EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 AND VASCULAR ENDOTHELIAL GROWTH FACTOR C IN FOREBRAIN
    Ward, M. C.
    Cunningham, A. M.
    [J]. NEUROSCIENCE, 2015, 303 : 544 - 557
  • [3] Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion
    Hlophe, Yvette N.
    Joubert, Anna M.
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (23) : 5743 - 5754
  • [4] Binding of pleiotrophin to vascular endothelial growth factor receptor 2 regulates endothelial cell migration
    Lamprou, M.
    Kastana, P.
    Choleva, E.
    Kofina, F.
    Tzoupis, H.
    Pantazaka, E.
    Sajib, M. S.
    Tselios, T.
    Mikelis, C. M.
    Papadimitriou, E.
    [J]. FEBS OPEN BIO, 2019, 9 : 131 - 132
  • [5] Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression
    Cai, Weibo
    Chen, Xiaoyuan
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 4267 - 4279
  • [6] Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in ovarian epithelial tumors
    Fu Xiao-yan
    Ding Ming-xing
    Zhang Ning
    Lin Xing-qiu
    Li Ji-cheng
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2007, 19 (02) : 124 - 130
  • [7] Expression of Vascular Endothelial Growth Factor-C and Vascular Endothelial Growth Factor Receptor-3 in Ovarian Epithelial Tumors
    傅晓艳
    丁明星
    张宁
    林兴秋
    李继承
    [J]. Chinese Journal of Cancer Research, 2007, (02) : 124 - 130
  • [8] Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck
    Neuchrist, C
    Erovic, BM
    Handisurya, A
    Fischer, MB
    Steiner, GE
    Hollemann, D
    Gedlicka, C
    Saaristo, A
    Burian, M
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2003, 25 (06): : 464 - 474
  • [9] Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2
    Zhao, Bojun
    Smith, Gill
    Cai, Jun
    Ma, Aihua
    Boulton, Mike
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (04) : 538 - 545
  • [10] Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung
    Janvier, A
    Nadeau, S
    Baribeau, J
    Perreault, T
    [J]. CRITICAL CARE MEDICINE, 2005, 33 (04) : 860 - 866